ABHD16B

Across TCGA pan-cancer cohorts, ABHD16B Mutation is linked to patient survival in 6 of 34 cancer types, making it the most broadly survival-associated ABHD16B data layer compared with 1 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ABHD16B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ABHD16B expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

HNSC, COAD, and UCEC are the cancer types where ABHD16B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.138	0.710	.001	24	view →
COAD	DFS	Median	All	0.189	0.691	.005	14	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	0.046	0.738	<.001	6	view →
SARC	DFS	Median	All	0.127	0.611	.049	3	view →
STAD	DFS	Median	II,III,IV	1.000	0.372	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ABHD16B–HNSC (OS)

Open the HNSC breakdown →